CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 180 enrolled
Drug / intervention
vitamin E +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06509581
NCT06509581N/ACompleted

Vitamin E Supplementation for Children With Transfusion Dependent Beta Thalassemia on Different Iron Chelators

Ain Shams University·interventional·Posted Jul 19, 2024·Updated Jul 19, 2024

In Brief

A clinical study evaluating vitamin E and PLACEBO for Beta-Thalassemia. Completed, enrolled 180 participants across 1 site.

Detailed Summary

repeated transfusions are the mainstay of disease management in most patients with transfusion dependent beta thalassemia.iron overload predispose to oxidative stress and tissue injury. oxidative stress play important role in pathogenesis of anemia in beta thalassemia. vitamin E is often depleted in thalassemia patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJul 19, 2024
Enrollment StartJul 5, 2021
Primary CompletionSep 11, 2022
Study CompletionOct 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.0 years ago

Interventions

vitamin Edietary

Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )

PLACEBOother

placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )